Glucagon-Like Peptide-1 Receptor Agonist and Postoperative Opioid Consumption in Gynecologic Surgery
- 12 June 2026
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104803
Abstract
No abstract availableKeywords
Funding Information
- Universidad Autónoma de Madrid
This publication has 22 references indexed in Scilit:
- Enhanced recovery in gynecologic surgery: institutional challenges and implementation frameworkInternational Journal of Gynecological Cancer, 2025
- GLP-1 agonists: a game changer in pain treatment and addictionPain Management, 2025
- Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021The Lancet, 2025
- Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring SurgeryAesthetic Surgery Journal, 2024
- Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use DisorderJAMA Network Open, 2024
- Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathyDiabetologia, 2024
- GLP-1 physiology informs the pharmacotherapy of obesityMolecular Metabolism, 2021
- Projected U.S. State-Level Prevalence of Adult Obesity and Severe ObesityNew England Journal of Medicine, 2019
- Postoperative pain management in the era of ERAS: An overviewBest Practice & Research Clinical Anaesthesiology, 2019
- A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programsGynecologic Oncology, 2016